Presentation Title

Investigating the role of endogenous immune response in HER2+ breast cancer patients that undergo Chemotherapeutic Trastuzumab therapy: Mayo Clinic SURF Program

Faculty Mentor

Dr. Knutson(PI), Dr. Valenzuela(faculty mentor)

Start Date

18-11-2017 9:30 AM

End Date

18-11-2017 9:45 AM

Location

9-271

Session

Bio Sciences 2

Type of Presentation

Oral Talk

Subject Area

biological_agricultural_sciences

Abstract

The objective of this study was to determine whether or not anti-HER2 antibody responses in HER2+ patients treated with chemotherapy and Trastuzumab would lead to better clinical outcomes. In this clinical trial, four types of patients were given the same treatment regimes from which serum was taken. The patient categories were: baseline patients, adjuvant patients, neo-adjuvant patients and metastatic patients. Baseline patients were individuals that had not yet received the treatment and acted as a negative control. In order to achieve our aim, we measured the IgG antibody response to Chemotherapeutic Trastuzumab from the patient serum samples against a variety of tumor antigens at different time points throughout treatment: before treatment (baseline), 2 months after treatment, 3 months after treatment and 4 months after treatment. HER2+ breast cancer patient serum samples were collected from venipunctures. A series of ELISA experiments were used to quantitate and analyze IgG antibody response against a variety of tumor antigens, which included TT (control), ICD, ECD, CEA, IGFBP-2 & P53. Using the data from the ELISA plates, computational analysis was carried out to measure the immune response. A standard curve was generated as a point of reference in order to extract interpolated values for a 1:50 dilution. These values provided the amount of antibody produced (mcg/mL) for each sample. This study is ongoing, so we cannot conclude the objective responses of patients with different treatment regimens to previous studies. However, results from this study support the trend that amplified tumor immunity contributes to efficacy of combination treatment. We hope to improve our study by collecting more patient samples after three months of treatment to observe an extensive trend for that particular time frame. And ultimately, our goal is to finish assaying all the samples in order to achieve stronger statistical significance in our patient responses.

Summary of research results to be presented

When comparing Her 2-ECD results to baseline, adjuvant patients revealed a decrease in antibody production after two months(2M) of treatment and it stabilized after four months(4M) of treatment. Neoadjuvant patients increased in antibody production at 2M and 4M and metastatic patients’ production slightly increased at 2M, and from 3M-4M it decreased. Her 2-ICD results showed that for adjuvant patients there was a decrease in antibody production from 2M-3M with a slight increase at 4M, neoadjuvant patients’ production decreased at 2M & 4M and metastatic patients’ production increased at 2M and decreased from 3M-4M. CEA results revealed that for adjuvant patients, antibody production was stable at 2M and 4M, neoadjuvant patients’ production decreased at 2M and 4M, and metastatic patients increased from 2M-4M. IGFBP-2 results showed a decrease in antibody production for adjuvant patients, neoadjuvant patients and metastatic patients from 2M-4M. P53 results indicated that for both adjuvant and neoadjuvant patients there was an increase in antibody production at 2M and 4M and for metastatic patients, there was a decrease in antibody production from 2M-4M. Overall, the results from this study could provide further evidence that amplified tumor immunity contributes to efficacy of combination treatment.

This document is currently not available here.

Share

COinS
 
Nov 18th, 9:30 AM Nov 18th, 9:45 AM

Investigating the role of endogenous immune response in HER2+ breast cancer patients that undergo Chemotherapeutic Trastuzumab therapy: Mayo Clinic SURF Program

9-271

The objective of this study was to determine whether or not anti-HER2 antibody responses in HER2+ patients treated with chemotherapy and Trastuzumab would lead to better clinical outcomes. In this clinical trial, four types of patients were given the same treatment regimes from which serum was taken. The patient categories were: baseline patients, adjuvant patients, neo-adjuvant patients and metastatic patients. Baseline patients were individuals that had not yet received the treatment and acted as a negative control. In order to achieve our aim, we measured the IgG antibody response to Chemotherapeutic Trastuzumab from the patient serum samples against a variety of tumor antigens at different time points throughout treatment: before treatment (baseline), 2 months after treatment, 3 months after treatment and 4 months after treatment. HER2+ breast cancer patient serum samples were collected from venipunctures. A series of ELISA experiments were used to quantitate and analyze IgG antibody response against a variety of tumor antigens, which included TT (control), ICD, ECD, CEA, IGFBP-2 & P53. Using the data from the ELISA plates, computational analysis was carried out to measure the immune response. A standard curve was generated as a point of reference in order to extract interpolated values for a 1:50 dilution. These values provided the amount of antibody produced (mcg/mL) for each sample. This study is ongoing, so we cannot conclude the objective responses of patients with different treatment regimens to previous studies. However, results from this study support the trend that amplified tumor immunity contributes to efficacy of combination treatment. We hope to improve our study by collecting more patient samples after three months of treatment to observe an extensive trend for that particular time frame. And ultimately, our goal is to finish assaying all the samples in order to achieve stronger statistical significance in our patient responses.